{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:40Z","timestamp":1790959360020,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ajo.2022.11.017","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:03:32Z","timestamp":1669046612000},"page":"35-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Ripasudil\u2013Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials"],"prefix":"10.1016","volume":"248","author":[{"given":"Hidenobu","family":"Tanihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6683-0144","authenticated-orcid":false,"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6810-0583","authenticated-orcid":false,"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9717-985X","authenticated-orcid":false,"given":"Toshiaki","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9130-0137","authenticated-orcid":false,"given":"Hideki","family":"Suganami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2022.11.017_bib0001","first-page":"85","article-title":"The Japan Glaucoma Society. guidelines for glaucoma (5th edition)","volume":"126","year":"2022","journal-title":"J Jpn Ophthalmol Soc"},{"key":"10.1016\/j.ajo.2022.11.017_bib0002","unstructured":"American Academy of Ophthalmology. Primary open-angle glaucoma preferred practice pattern 2020. Accessed June 7, 2022. https:\/\/www.aao.org\/preferred-practice-pattern\/primary-open-angle-glaucoma-ppp."},{"key":"10.1016\/j.ajo.2022.11.017_sbref0003","series-title":"Terminology and guidelines for glaucoma","year":"2022"},{"issue":"3","key":"10.1016\/j.ajo.2022.11.017_bib0004","first-page":"233","article-title":"Compliance in patients prescribed eyedrops for glaucoma","volume":"26","author":"Patel","year":"1995","journal-title":"Ophthalmic Surg"},{"issue":"11 Suppl","key":"10.1016\/j.ajo.2022.11.017_bib0005","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","article-title":"A comprehensive perspective on patient adherence to topical glaucoma therapy","volume":"116","author":"Tsai","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.017_bib0006","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0161-6420(02)01974-7","article-title":"Blindness in patients with treated open-angle glaucoma","volume":"110","author":"Chen","year":"2003","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.017_bib0007","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","article-title":"The association between medication adherence and visual field progression in the Collaborative Initial Glaucoma Treatment Study","volume":"127","author":"Newman-Casey","year":"2020","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2022.11.017_bib0008","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/02713683.2013.874444","article-title":"Effects of K-115, a Rho-kinase inhibitor, on aqueous humor dynamics in rabbits","volume":"39","author":"Isobe","year":"2014","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ajo.2022.11.017_bib0009","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1749-6632.1995.tb32392.x","article-title":"Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys","volume":"763","author":"Burke","year":"1995","journal-title":"Ann NY Acad Sci"},{"issue":"12","key":"10.1016\/j.ajo.2022.11.017_bib0010","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archopht.1995.01100120044006","article-title":"Effects of brimonidine on aqueous humor dynamics in human eyes","volume":"113","author":"Toris","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2022.11.017_bib0011","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0039-6257(96)82027-3","article-title":"Preclinical evaluation of brimonidine","volume":"41","author":"Burke","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajo.2022.11.017_bib0012","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/02713688609015134","article-title":"Ocular effects of a relatively selective alpha 2 agonist (UK-14, 304-18) in cats, rabbits and monkeys","volume":"5","author":"Burke","year":"1986","journal-title":"Curr Eye Res"},{"issue":"7","key":"10.1016\/j.ajo.2022.11.017_bib0013","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.017_bib0014","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/aos.12599","article-title":"Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study","volume":"93","author":"Tanihara","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2022.11.017_bib0015","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ophtha.2007.03.016","article-title":"Predictors of long-term progression in the early manifest glaucoma trial","volume":"114","author":"Leske","year":"2007","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2022.11.017_bib0016","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2007.04.040","article-title":"Intercurrent factors associated with the development of open-angle glaucoma in the European Glaucoma Prevention Study","volume":"144","author":"Miglior","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"6654","key":"10.1016\/j.ajo.2022.11.017_bib0017","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/40187","article-title":"Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension","volume":"389","author":"Uehata","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ajo.2022.11.017_bib0018","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/oxfordjournals.jbchem.a021401","article-title":"The small GTPase Rho: cellular functions and signal transduction","volume":"120","author":"Narumiya","year":"1996","journal-title":"J Biochem"},{"issue":"10","key":"10.1016\/j.ajo.2022.11.017_bib0019","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","article-title":"Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115","volume":"131","author":"Tanihara","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2022.11.017_bib0020","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1038\/s41598-019-40255-9","article-title":"Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% ripasudil ophthalmic solution clinical trial","volume":"9","author":"Sakamoto","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.017_bib0021","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2022.11.017_bib0022","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.017_bib0023","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s12325-021-02023-y","article-title":"Long-term intraocular pressure-lowering effects and adverse events of ripasudil in patients with glaucoma or ocular hypertension over 24 months","volume":"39","author":"Tanihara","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.ajo.2022.11.017_bib0024","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0002-9394(98)00286-4","article-title":"Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group","volume":"127","author":"Katz","year":"1999","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2022.11.017_bib0025","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/S0161-6420(98)91048-X","article-title":"Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2","volume":"105","author":"LeBlanc","year":"1998","journal-title":"Ophthalmology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422004391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422004391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:51:59Z","timestamp":1757598719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939422004391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":25,"alternative-id":["S0002939422004391"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2022.11.017","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ripasudil\u2013Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2022.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}